Her neurological examination was remarkable for weakness 4/5 in the left arm and 4+/5 in the left leg. An MRI demonstrated increased T2 signal intensity surrounding the AVM (Fig. 3) . Corticosteroid therapy was initiated at that time, with a prescription for slow tapering off of the dosage over a month. The patient experienced a partial clinical response to the steroids with slight improvement in her headache but minimal change in her weakness. After 3 weeks, while on a lower dose of steroid medication, she returned to the emergency department with severe headache, nausea, vomiting, and unchanged weakness. She subsequently developed a left-sided pronator drift. An MRI study demonstrated persistent perilesional edema (Fig. 4) . She was restarted on a high-dose steroid taper, and vitamin E and pentoxifylline were added. She continued to experience severe headaches intermittently; her hemiparesis remained stable. Approximately 1 month later (2 months after the onset of her symptoms) her headaches became severe enough to restrict her activity to bed rest only, causing her to present to the emergency department again. Her neurological examination findings were stable. Both MRI and CT demonstrated persistent perilesional edema (Fig. 5) . She was admitted to the hospital and treated with an increased dose of corticosteroids without significant improvement in her symptoms. Her severe headache, which was refractory to pain management with intravenous narcotics and steroids, kept her incapacitated and essentially bed bound.
Considering the inadequate response to corticosteroids and her severe refractory symptoms, we discussed the option of treating the perilesional edema with bevacizumab. After informed consent was obtained, the patient was initially treated with a dose of 2.5 mg/kg, which she tolerated without incident. She experienced dramatic improvement in her headache the day after her infusion. She was able to ambulate without assistance and did not require further intravenous narcotic therapy. One week later she returned for evaluation and additional treatment. A CT study demonstrated no complications from treatment with her initial dose, and therefore, a dose of 7.5 mg/ kg was administered (Fig. 6 ). On follow-up at 2 weeks ( Fig. 7 ) and 6 weeks ( Fig. 8) after the initial infusion of bevacizumab, her symptoms continued to improve. Her headache was intermittent and tolerable, managed with tramadol, and her steroid had been tapered off. Her weakness had improved to 4+/5 in her left lower extremity. She continued to have a pronator drift and slight hyperreflexia on the left. At 2 weeks' follow-up, MRI demonstrated stable perilesional edema on T2-weighted images, and MR angiography demonstrated no abnormal shunting in the region of the AVM (Fig. 7) . A CT study and MRI performed at 6 weeks after the initial administration of bevacizumab demonstrated a dramatic decrease in contrast enhancement in the area of the AVM and a decrease in T2 signal around the AVM (Fig. 8) . Follow-up at 1 year after GKS treatment and 10 weeks after the administration of bevacizumab demonstrated clinical improvement with infrequent use of tramadol for headache and no use of steroid agents. Neurological examination showed 4+/5 strength in the left arm and leg and a slight left pronater drift. She was able to return to school and activities of daily living without difficulty. Digital subtraction angiography performed at this time demonstrated obliteration of the AVM nidus with no evidence of abnormal shunting (Fig. 9 ).
Discussion
Radiation-induced MRI changes occur in 36% of AVM cases treated with SRS at our institution. 25 These changes typically occur between 6 and 25 months after treatment and last for 2 to 79 months. The MRI findings were not associated with symptoms in 17% of cases, and these cases were managed expectantly. Symptomatic patients presented with headaches and new neurological deficits, as in our report, and were generally treated only with corticosteroid therapy. 25, 26 In these cases perilesional edema typically heralded obliteration of the malformation. In the case presented in this report, the AVM was in an eloquent area, thus the patient developed a focal neurological deficit. Her severe headache, which was the most functionally limiting symptom, was a significant clinical feature as well. Bevacizumab has been used successfully for severe, symptomatic perilesional edema related to radiation necrosis from fractionated external beam treatments.
9,10,17,23
If VEGF is a final common mediator of perilesional edema due to tumors, necrosis, or AVMs treated with radiosurgery, then there may be a rational basis for using bevacizumab in these cases. 18 The side effect profile and cost of bevacizumab limit its potential use for this indication given that corticosteroids are inexpensive and typically control perilesional edema safely and effectively.
6,8,11,15
Nevertheless, in cases in which edema is refractory to corticosteroids and the patient is symptomatic, it may be reasonable to consider the use of bevacizumab, especially when symptoms are severe and operative intervention would have significant morbidity, as in our case.
The administration of this medication should be supervised by clinicians familiar with prescribing this medication and with the pertinent side effects. In particular, the risk of bevacizumab in patients with vascular malformations known to have a tendency to hemorrhage must be weighed against the benefits and alternative therapeutic options (for example, open resection or continued management with narcotic and corticosteroid agents). When bevacizumab is used in GKS patients with posttreatment edema and necrosis, the patients must be monitored closely with clinical examination and serial imaging for improvement in the edema and potential development of bevacizumab-associated toxicity. Common severe adverse events associated with the use of bevacizumab are seizure (6%), fatigue (3.6%), hypertension (8.3%), and neutropenia, diarrhea, and pneumonia (1.2% each).
5 Specifically related to neurosurgical complications, bevacizumab has been associated with worse wound healing if given before a procedure compared with healing in groups not treated with bevacizumab or treated postoperatively.
4

Conclusions
We report the first case of bevacizumab used for treatment of corticosteroid-refractory, symptomatic, and progressive edema due to an AVM after GKS. Given that this is a single case report, we cannot presume to provide proof of a causal relationship between bevacizumab and the resolution of perilesional edema. However, when evaluated in the context of the recent trial of bevacizumab for perilesional edema related to radiation necrosis, this case provides further evidence that bevacizumab may be a useful tool in the armamentarium of clinicians treating these difficult cases. Based on this evidence, we believe that the efficacy and safety of bevacizumab should be rigorously evaluated for severe, refractory cases of perilesional edema. 
